Sharma Dhruva, Krishnan Ganapathy Subramaniam, Sharma Neha, Chandrashekhar Anitha
Department of Cardiothoracic and Vascular Surgery, SMS Medical College & Attached Hospitals, J L N Marg, Jaipur, 302001 Rajasthan India.
Institute of Heart and Lung Transplant and Mechanical Circulatory Support, MGM Healthcare, No. 72, Nelson Manickam Road, Aminjikarai, Chennai, 600029 Tamil Nadu India.
Indian J Thorac Cardiovasc Surg. 2022 Sep;38(5):497-505. doi: 10.1007/s12055-022-01388-1. Epub 2022 Jul 14.
Lung transplantation is an effective treatment option for selected patients suffering from end-stage lung disease. More intensive immunosuppression is enforced after lung transplants owing to a greater risk of rejection than after any other solid organ transplants. The commencing of lung transplantation in the modern era was in 1983 when the Toronto Lung Transplant Group executed the first successful lung transplant. A total of 43,785 lung transplants and 1365 heart-lung transplants have been performed from 1 Jan 1988 until 31 Jan 2021. The aim of this review article is to discuss the existing immunosuppressive strategies and emerging agents to prevent acute and chronic rejection in lung transplantation.
肺移植是终末期肺病特定患者的一种有效治疗选择。由于肺移植后排斥反应的风险比其他任何实体器官移植后都要高，因此术后会实施更强的免疫抑制措施。现代肺移植始于1983年，当时多伦多肺移植小组完成了首例成功的肺移植手术。从1988年1月1日至2021年1月31日，共进行了43785例肺移植和1365例心肺移植。这篇综述文章的目的是讨论现有的免疫抑制策略以及预防肺移植急性和慢性排斥反应的新型药物。
